Apellis Pharmaceuticals, Inc. (BIT:1APLS)

Market Cap	2.64B
Revenue (ttm)	642.58M
Net Income (ttm)	-194.29M
Shares Out	n/a
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	240
Open	16.88
Previous Close	16.88
Day's Range	16.88 - 16.88
52-Week Range	16.37 - 17.25
Beta	n/a
RSI	n/a
Earnings Date	Jul 31, 2025

About Chuy's Holdings

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem ce...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 710
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1APLS

Financial Performance

In 2024, Apellis Pharmaceuticals's revenue was $781.37 million, an increase of 97.02% compared to the previous year's $396.59 million. Losses were -$197.88 million, -62.57% less than in 2023.